KEYMED BIOSCIENCES
Keymed Biosciences develops innovative monoclonal antibody drugs and other therapeutic protein drugs for cancer, autoimmune diseases, and infectious diseases.
KEYMED BIOSCIENCES
Social Links:
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2016-01-01
Address:
Chengdu, Sichuan, China
Country:
China
Website Url:
http://www.en.keymedbio.com
Total Employee:
11+
Status:
Active
Contact:
028-88610620
Email Addresses:
[email protected]
Current Advisors List
Current Employees Featured
Official Site Inspections
http://www.en.keymedbio.com
- Host name: 47.116.187.136
- IP address: 47.116.187.136
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Keymed Biosciences"
Keymed Biosciences - Crunchbase Company Profile
En.keymedbio.com ; 154,165; Highlights. ... Contact Email [email protected]; Phone Number 028-88610620; Keymed Biosciences develops innovative …See details»
康诺亚生物医药科技成都有限公司
康诺亚生物医药科技有限公司总部位于成都，康诺亚是一家专注研究创新单克隆抗体药物和其它治疗性蛋白药物研发与产业化的医药科技公司，康诺亚于2021年7月8日正式在香港联合交易所主板成功上市。See details»
康诺亚生物 - Keymed Biosciences | 首页
康诺亚生物医药科技有限公司总部位于成都，专注研究创新单克隆抗体药物和其它治疗性蛋白药物研发与产业化，康诺亚于2021年7月8日在香港联合交易所主板上市。See details»
Keymed Biosciences Inc. (2162.HK) - Yahoo Finance
See the company profile for Keymed Biosciences Inc. (2162.HK) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Keymed Biosciences - Overview, News & Similar companies
Mar 25, 2024 en.prnasia.com . Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for …See details»
Keymed Biosciences Company Profile | Management and
[email protected]: 5: last: [email protected]: Your Questions, Our Answers Get Free Access to Keymed Biosciences Contacts Info. What is Keymed Biosciences revenue? …See details»
Keymed Biosciences Inc. 康諾亞生物醫藥科技有限公司 2021
Www.keymedbio.com STOCK CODE 2162 LISTING DATE July 8, 2021. 2021 T 7 Chairman’s Statement Dear investors, On behalf of the Board of Directors of Keymed, I would like to …See details»
Keymed Biomedical Technology (Chengdu) Co., Ltd.
Explore Keymed Biomedical Technology (Chengdu) Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 86 clinical trials, 2 news, and 3 literature, Disease Domain:Immune …See details»
About Us - 康诺亚生物医药科技成都有限公司 - en.keymedbio.com
康诺亚生物医药科技有限公司总部位于成都，康诺亚是一家专注研究创新单克隆抗体药物和其它治疗性蛋白药物研发与产业化的医药科技公司，康诺亚于2021年7月8日正式在香港联合交易所 …See details»
Lepu Biopharma and Keymed Jointly Announces Global Exclusive …
Feb 23, 2023 Email: [email protected]. Last. Next. Back to list. 2024-09-27 12:26. 2024 Interim Report. Explore the details. 2024-04-25 18:28. 2023 Annual Report. Explore the …See details»
KeyMed Biosciences - PitchBook
KeyMed Biosciences General Information Description. Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house …See details»
Keymed and Lepu Biopharma Jointly Announce Global Exclusive …
CHENGDU, China, February 23, 2023 – Keymed Biosciences Inc., (“Keymed”) (Stock Code: 02162 HK)and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a …See details»
管理团队 - 康诺亚生物 - Keymed Biosciences | 首页
康诺亚生物医药科技有限公司总部位于成都，专注研究创新单克隆抗体药物和其它治疗性蛋白药物研发与产业化，康诺亚于2021年7月8日在香港联合交易所主板上市。See details»
Keymed Biosciences - Craft
Oct 29, 2024 Keymed Biosciences ¥354.1 m in annual revenue in FY 2023. See insights on Keymed Biosciences including office locations, competitors, revenue, financials, executives, …See details»
2025 - 康诺亚生物 - Keymed Biosciences | 首页
· 潜在同类最优CD38单抗CM313 与Timberlyne 达成独家授权许可协议 · CM336授权合作公司Ouro Medicines融资1.2亿美元，加速产品后续开发. · 康诺亚和诺诚健华就CD20xCD3双 …See details»
KeyMed Biosciences Inc, 2162:HKG profile - FT.com - Financial Times
KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology …See details»
KeyMedBio 2021 Interim Presentation
KEYMEDBIOSCIENCES Keymedat a Glance COMPANY OVERVIEW 6 We are a biotechnology company with multiple clinical-stage assets, each of them being the leading contender within …See details»
Keymed Biosciences Announces Approval Of Stapokibart For The …
CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has …See details»
Keymed Biosciences Announces 2022 Annual Results
Mar 17, 2023 Media ：[email protected] IR ：[email protected] Previous：PRIMARY STUDY ENDPOINTS FROM PHASE III CLINICAL TRIAL OF CM310 FOR THE TREATMENT …See details»
Keymed Bio 2021 Annual Results Presentation
Keymed Bio 2021 Highlights • Core Pipeline • CM310 (IL-4Rα): We completed the Phase IIb trail for moderate-to severe AD in adult in 2021, and published the clinical result. Phase III clinical …See details»